Trial Profile

Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sildenafil (Primary)
Indications Chronic heart failure; Pulmonary arterial hypertension
Focus Therapeutic Use
Sponsors Hanmi Pharmaceutical

Most Recent Events

24 Nov 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
24 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
14 Mar 2016 Planned End Date changed from 1 Feb 2015 to 1 May 2017, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com